Cover Image
市場調查報告書

mTOR抑制劑的開發平台分析

mTOR Inhibitors Therapeutics - Pipeline Analysis 2017, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

出版商 P&S Market Research Pvt. Ltd 商品編碼 606423
出版日期 內容資訊 英文 124 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
mTOR抑制劑的開發平台分析 mTOR Inhibitors Therapeutics - Pipeline Analysis 2017, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments
出版日期: 2017年12月01日 內容資訊: 英文 124 Pages
簡介

本報告提供mTOR抑制劑的全球市場調查,開發平台概要,推動市場要素及阻礙因素分析,各實驗階段、分子類型、投藥途徑的開發平台趨勢,藥物簡介,競爭環境,主要企業簡介等彙整。

第1章 調查背景

  • 調查目的
  • 定義
  • 調查範圍
    • 開發平台分析:臨床試驗的各階段
    • 開發平台分析:各分子類型
    • 開發平台分析:各給藥途徑
  • 主要的相關利益者

第2章 調查手法

  • 2次調查
  • 本調查

第3章 摘要整理

第4章 開發平台預測

  • 市場概要
  • 促進因素
    • 癌症罹患率的上升和醫療費的增加
    • 技術發展
  • 阻礙因素
    • 安全性的疑慮和風險因素
    • mTOR抑制劑的開發平台分析

第5章 mTOR抑制劑的開發平台分析:各階段

  • 第三階段實驗:藥物簡介
    • Ipatasertib
    • 其他
  • 第二階段實驗:藥物簡介
    • LY3023414
    • 其他
  • 第一階段實驗:藥物簡介
    • VDC597
    • 其他
  • 臨床試驗前:藥物簡介
    • VPE001
    • 其他
  • 藥物研發:藥物簡介
    • VEA005
    • 其他
  • 開發中止的治療藥

第6章 臨床試驗分析

  • mTOR抑制劑的開發平台分析 - 各地區
  • mTOR抑制劑的開發平台分析 - 各檢測狀況

第7章 競爭情形

  • 主要企業的基準
  • SWOT分析

第8章 企業簡介

  • Eli Lilly and Company
  • AstraZeneca Plc
  • 其他企業

第9章 附錄

  • 簡稱
  • 相關調查
目錄

The mechanistic/mammalian target of rapamycin (mTOR) is a serine threonine protein kinase, that belongs to the phosphatidylinositol-3-kinase-related kinase family. Molecules in this family have more than 2,500 amino acids, and they harbor a kinase domain at their C-terminals. It has been observed that the increasing prevalence of cancer along with its high healthcare cost, globally, has been driving the growth of mTOR inhibitors pipeline. For instance, the number of people living beyond cancer diagnosis reached around 14.5 million in 2014 and is expected to increase to 19 million, by 2024. In 2010, approximately $125 million was spent on cancer care in the U.S., and it is expected to reach $156 million, by 2020.

Other factors strengthening the mTOR inhibitors pipeline include smoking, obesity unhygienic food, and allergy. The study analyzed that mTOR inhibitors therapeutics pipeline comprises approximately 30 drug candidates in different stages of development.

Insights on pipeline segments

According to the research findings, most of the drug candidates that act as mTOR inhibitors are being developed as small molecules, further supported by the fact that small molecules have several advantages such as it can be manufactured with production rate higher than any other molecule types.

Positive Clinical Results of mTOR Inhibitors Therapeutics Candidates

The positive clinical results of mTOR inhibitors drug candidates is a key factor driving the pipeline growth. For instance, F. Hoffman-La-Roche AG has developed a drug candidate, ipatasertib, that acts as mTOR inhibitors. The Phase II clinical results (Study ID: NCT02162719) of the drug candidate were published in the Lancet Oncology journal. It has been observed that progression-free survival was longer in patients who received ipatasertib as compared in those who received placebo.

Technological Advancements for mTOR Inhibitors Therapeutics Drug Development

Most of the companies are developing innovative technologies for the synthesis or production of mTOR inhibitors. For instance, PHusis Therapeutics Inc. is using its computational modeling platform namely, PHuDock, that identify inhibitors of proteins which promotes the growth of cancer cells. Using PHuDock, X-ray structural information and surface plasmon resonance spectroscopic measurements of selected drug-like molecules, PHusis is rapidly and efficiently identifying agents involving toxicity studies, that selectively inhibit the activity of a number of these cancers driving proteins. PHuDock is applied to lead identification and optimization, as well as to predict the compounds off-target properties and toxicity, therefore delivering novel and highly effective agents with low toxicity.

These technologically advanced platforms enable the players in the pipeline to develop effective new therapies rapidly, that are cost effective and potentially have lower risk of toxicity, and relative to traditional approaches. Thus, these technological advancements act as a key driver for the pipeline growth.

Some of the key players involved in the development of mTOR inhibitors therapeutics include F. Hoffman-La-Roche AG, Pfizer Inc., and resTORbio Inc.

Table of Content

Chapter 1. Research Background

  • 1.1 Research Objectives
  • 1.2 Definition
  • 1.3 Research Scope
    • 1.3.1 Pipeline Analysis by Phase
    • 1.3.2 Pipeline Analysis by Molecule Type
    • 1.3.3 Pipeline Analysis by Route of Administration
  • 1.4 Key Stakeholders

Chapter 2. Research Methodology

  • 2.1 Secondary Research
  • 2.2 Primary Research
    • 2.2.1 By Industry Participant
    • 2.2.2 By Company Type

Chapter 3. Executive Summary

Chapter 4. Pipeline Outlook

  • 4.1 Overview
  • 4.2 Key Drivers
    • 4.2.1 Increasing Prevalence of Cancer and Rising Healthcare Cost
    • 4.2.2 Technical Advancements
  • 4.3 Key Barrier
    • 4.3.1 Safety Concerns and Risk factors
  • 4.4 mTOR Inhibitor Therapeutics Pipeline Analysis
    • 4.4.1 Pipeline Analysis by Phase
    • 4.4.2 Pipeline Analysis by Molecule Type
    • 4.4.3 Pipeline Analysis by Route of Administration
    • 4.4.4 Pipeline Analysis by Company

Chapter 5. mTOR Inhibitor Therapeutics Pipeline Analysis by Phase (2017) 30

  • 5.1 Phase III
    • 5.1.1 Ipatasertib
      • 5.1.1.1 Clinical trials
      • 5.1.1.2 Clinical results
      • 5.1.1.3 Strategic developments
    • 5.1.2 XXXX
      • 5.1.2.1 Clinical trials
  • 5.2 Phase II
    • 5.2.1 LY3023414
      • 5.2.1.1 Clinical trials
    • 5.2.2 XXXX
      • 5.2.2.1 Pre-Clinical studies
      • 5.2.2.2 Clinical trials
      • 5.2.2.3 Clinical results
      • 5.2.2.4 Others
    • 5.2.3 XXXX
      • 5.2.3.1 Clinical trials
      • 5.2.3.2 Strategic developments
    • 5.2.4 XXXX
      • 5.2.4.1 Clinical trials
      • 5.2.4.2 Clinical results
      • 5.2.4.3 Strategic developments
    • 5.2.5 XXXX
      • 5.2.5.1 Clinical trials
      • 5.2.5.2 Strategic developments
      • 5.2.5.3 Grant
      • 5.2.5.4 Technology
    • 5.2.6 XXXX
      • 5.2.6.1 Clinical trials
      • 5.2.6.2 Designation
    • 5.2.7 XXXX
      • 5.2.7.1 Clinical trials
      • 5.2.7.2 Clinical results
    • 5.2.8 XXXX
      • 5.2.8.1 Pre-Clinical Studies
      • 5.2.8.2 Clinical trials
      • 5.2.8.3 Clinical results
      • 5.2.8.4 Strategic developments
      • 5.2.8.5 Designation
      • 5.2.8.6 Grant
  • 5.3 Phase I
    • 5.3.1 VDC597
    • 5.3.2 XXXX
      • 5.3.2.1 Clinical trials
  • 5.4 Pre-Clinical
    • 5.4.1 VPE001
      • 5.4.1.1 Strategic developments
    • 5.4.2 XXXX
      • 5.4.2.1 Pre-Clinical studies
      • 5.4.2.2 Others
    • 5.4.3 XXXX
      • 5.4.3.1 Technology
      • 5.4.3.2 Strategic developments
    • 5.4.4 XXXX
      • 5.4.4.1 Technology
    • 5.4.5 XXXX
    • 5.4.6 XXXX
      • 5.4.6.1 Technology
      • 5.4.6.2 Designation
    • 5.4.7 XXXX
      • 5.4.7.1 Others
      • 5.4.7.2 Technology
    • 5.4.8 XXXX
      • 5.4.8.1 Pre-Clinical studies
      • 5.4.8.2 Strategic developments
      • 5.4.8.3 Technology
  • 5.5 Discovery
    • 5.5.1 VEA005
      • 5.5.1.1 Strategic developments
    • 5.5.2 XXXX
      • 5.5.2.1 Strategic developments
    • 5.5.3 XXXX
      • 5.5.3.1 Strategic developments
    • 5.5.4 XXXX
      • 5.5.4.1 Strategic developments
    • 5.5.5 XXXX
      • 5.5.5.1 Strategic developments
      • 5.5.5.2 Technology
    • 5.5.6 XXXX
      • 5.5.6.1 Others
    • 5.5.7 XXXX
      • 5.5.7.1 Technology
  • 5.6 Unknown Phase
    • 5.6.1 Non-Steroidal Small Molecule Drug
  • 5.7 Discontinued

Chapter 6. Clinical Trials Analysis

  • 6.1 Clinical Trials by Region for mTOR Inhibitors Therapeutics Pipeline Analysis 2017
  • 6.2 Clinical Trials by Trial Status for mTOR Inhibitors Therapeutics Pipeline Analysis 2017

Chapter 7. Competitive Landscape

  • 7.1 Key Players Benchmarking for mTOR inhibitors Therapeutics Pipeline
  • 7.2 SWOT Analysis of mTOR inhibitor Therapeutics Pipeline
    • 7.2.1 Strengths
    • 7.2.2 Weaknesses
    • 7.2.3 Opportunities
    • 7.2.4 Threats

Chapter 8. Company Profiles

  • 8.1 Eli Lilly & Company
    • 8.1.1 Business Overview
    • 8.1.2 Product & Service Offerings
  • 8.2 AstraZeneca Plc
    • 8.2.1 Business Overview
    • 8.2.2 Product & Service Offerings
  • 8.3 Company 3
    • 8.3.1 Business Overview
    • 8.3.2 Product & Service Offerings
  • 8.4 Company 4
    • 8.4.1 Business Overview
    • 8.4.2 Product & Service Offerings
  • 8.5 Company 5
    • 8.5.1 Business Overview
    • 8.5.2 Product & Service Offerings
  • 8.6 Company 6
    • 8.6.1 Business Overview
    • 8.6.2 Product & Service Offerings
  • 8.7 Company 7
    • 8.7.1 Business Overview
    • 8.7.2 Product & Service Offerings
  • 8.8 Company 8
    • 8.8.1 Business Overview
    • 8.8.2 Product & Service Offerings
  • 8.9 Company 9
    • 8.9.1 Business Overview
    • 8.9.2 Product & Service Offerings
  • 8.1 Company 10
    • 8.10.1 Business Overview
    • 8.10.2 Product & Service Offerings

Chapter 9. Appendix

  • 9.1 Abbreviations
  • 9.2 Related Reports

LIST OF TABLES

  • TABLE 1 PIPELINE ANALYSIS OF MTOR THERAPEUTICS, BY COMPANY (2017)
  • TABLE 2 DESCRIPTION OF IPATASERTIB
  • TABLE 3 CLINICAL TRIALS OF IPATASERTIB
  • TABLE 4 DESCRIPTION OF XXXX
  • TABLE 5 CLINICAL TRIALS OF XXXX
  • TABLE 6 DESCRIPTION OF LY3023414
  • TABLE 7 CLINICAL TRIALS OF LY3023414
  • TABLE 8 DESCRIPTION OF XXXX
  • TABLE 9 CLINICAL TRIALS OF XXXX
  • TABLE 10 DESCRIPTION OF XXXX
  • TABLE 11 DESCRIPTION OF XXXX
  • TABLE 12 CLINICAL TRIALS OF XXXX
  • TABLE 13 DESCRIPTION OF XXXX
  • TABLE 14 CLINICAL TRIALS OF XXXX
  • TABLE 15 DESCRIPTION OF XXXX
  • TABLE 16 CLINICAL TRIALS OF XXXX
  • TABLE 17 DESCRIPTION OF XXXX
  • TABLE 18 CLINICAL TRIALS OF XXXX
  • TABLE 19 DESCRIPTION OF XXXX
  • TABLE 20 CLINICAL TRIALS OF XXXX
  • TABLE 21 DESCRIPTION OF VDC597
  • TABLE 22 DESCRIPTION OF XXXX
  • TABLE 23 CLINICAL TRIALS OF XXXX
  • TABLE 24 DESCRIPTION OF VPE001
  • TABLE 25 DESCRIPTION OF XXXX
  • TABLE 26 DESCRIPTION OF XXXX
  • TABLE 27 DESCRIPTION OF XXXX
  • TABLE 28 DESCRIPTION OF XXXX
  • TABLE 29 DESCRIPTION OF XXXX
  • TABLE 30 DESCRIPTION OF XXXX
  • TABLE 31 DESCRIPTION OF XXXX
  • TABLE 32 DESCRIPTION OF VEA005
  • TABLE 33 DESCRIPTION OF XXXX
  • TABLE 34 DESCRIPTION OF XXXX
  • TABLE 35 DESCRIPTION OF XXXX
  • TABLE 36 DESCRIPTION OF XXXX
  • TABLE 37 DESCRIPTION OF XXXX
  • TABLE 38 DESCRIPTION OF XXXX
  • TABLE 39 DESCRIPTION OF NON-STEROIDAL SMALL MOLECULE DRUG
  • TABLE 40 DESCRIPTION OF DISCONTINUED DRUGS
  • TABLE 41 ELI LILLY & COMPANY - AT A GLANCE
  • TABLE 42 ASTRAZENECA PLC - AT A GLANCE
  • TABLE 43 COMPANY 3 - AT A GLANCE
  • TABLE 44 COMPANY 4 - AT A GLANCE
  • TABLE 45 COMPANY 5 - AT A GLANCE
  • TABLE 46 COMPANY 6 - AT A GLANCE
  • TABLE 47 COMPANY 7 - AT A GLANCE
  • TABLE 48 COMPANY 8 - AT A GLANCE
  • TABLE 49 COMPANY 9 - AT A GLANCE
  • TABLE 50 COMPANY 10 - AT A GLANCE

LIST OF FIGURES

  • FIG 1 RESEARCH METHODOLOGY
  • FIG 2 SPLIT OF PRIMARY AND SECONDARY RESEARCH
  • FIG 3 BREAKDOWN OF PRIMARY RESEARCH BY INDUSTRY PARTICIPANT
  • FIG 4 BREAKDOWN OF PRIMARY RESEARCH BY COMPANY TYPE
  • FIG 5 CELL SIGNALING PATHWAYS
  • FIG 6 GENE RELATED TO MTOR
  • FIG 7 MTOR INHIBITOR THERAPEUTICS UNDER DEVELOPMENT (2017)
  • FIG 8 MTOR INHIBITOR THERAPEUTICS PIPELINE SPLIT, BY MOLECULE TYPE (2017)
  • FIG 9 MTOR THERAPEUTIC PIPELINE SPLIT, BY ROUTE OF ADMINISTRATION (2017)
  • FIG 10 BREAKDOWN OF CLINICAL TRIALS, BY REGION
  • FIG 11 BREAKDOWN OF CLINICAL TRIALS, BY TRIAL STATUS
  • FIG 12 KEY PLAYERS BENCHMARKING
  • FIG 13 SWOT ANALYSIS
Back to Top